EP 1261371 A4 20050413 - MEMBRANE ESTROGEN RECEPTOR-DIRECTED THERAPY IN BREAST CANCER
Title (en)
MEMBRANE ESTROGEN RECEPTOR-DIRECTED THERAPY IN BREAST CANCER
Title (de)
AUF DEN MEMBRANÖSTROGENREZEPTOR AUSGERICHTETE THERAPIE FÜR BRUSTKREBS
Title (fr)
THERAPIE DIRIGEE SUR LE RECEPTEUR MEMBRANAIRE DES OESTROGENES, DANS LE CANCER DU SEIN
Publication
Application
Priority
- US 0105897 W 20010223
- US 18502600 P 20000225
Abstract (en)
[origin: WO0162288A1] Methods of diagnosing and treating mammalian tumors with molecules including anti-estrogen receptor immunoglobulin polypeptides are provided. In an illustrative embodiment, anti-estrogen receptor immunoglobulin polypeptides specific to distinct epitopes of the ligand-binding domain of estrogen receptor are contacted with membrane-associated estrogen receptor under conditions which allow binding of the anti-estrogen receptor immunoglobulin polypeptide to a degree sufficient to inhibit tumor growth by inhibiting the activation of the membrane-associated estrogen receptor. Injectable compositions for treating certain mammalian tumors with monoclonal antibodies and methods for diagnosing mammalian cancers which express an estrogen receptor associated with the surface membrane of the cells are also disclosed. Further, alternate methods for blocking intracellular signal transduction emanating from the activation of membrane-associated estrogen receptor forms are also presented. These approaches also appear sufficient to inhibit tumor growth.
IPC 1-7
IPC 8 full level
A61K 45/00 (2006.01); A61K 39/395 (2006.01); A61K 47/48 (2006.01); A61K 51/00 (2006.01); A61P 15/00 (2006.01); A61P 35/00 (2006.01); A61P 43/00 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01); C12N 15/113 (2010.01); A61K 38/00 (2006.01)
CPC (source: EP)
A61K 47/6849 (2017.07); A61P 15/00 (2017.12); A61P 35/00 (2017.12); A61P 43/00 (2017.12); C07K 16/2869 (2013.01); C07K 16/32 (2013.01); C12N 15/1138 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C12N 2310/315 (2013.01)
Citation (search report)
- [X] KUNISUE H ET AL: "ANTI-HER2 ANTIBODY ENHANCES THE GROWTH INHIBITORY EFFECT OF ANTI-OESTROGEN ON BREAST CANCER CELLS EXPRESSING BOTH OESTROGEN RECEPTORS AND HER2", BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 82, no. 1, January 2000 (2000-01-01), pages 46 - 51, XP001008510, ISSN: 0007-0920
- [X] WITTERS LOIS M ET AL: "Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody", BREAST CANCER RESEARCH AND TREATMENT, vol. 42, no. 1, 1997, pages 1 - 5, XP002304672, ISSN: 0167-6806
- [X] MOREY ANJALI K ET AL: "Estrogen and progesterone inhibit vascular smooth muscle proliferation", ENDOCRINOLOGY, vol. 138, no. 8, 1997, pages 3330 - 3339, XP002304840, ISSN: 0013-7227
- [X] SOMJEN DALIA ET AL: "Nongenomic effects of an anti-idiotypic antibody as an estrogen mimetic in female human and rat osteoblasts", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 65, no. 1, 1997, pages 53 - 66, XP002304841, ISSN: 0730-2312
- [A] ABBONDANZA CIRO ET AL: "Characterization and epitope mapping of a new panel of monoclonal antibodies to estradiol receptor", STEROIDS, vol. 58, no. 1, 1993, pages 4 - 12, XP001183746, ISSN: 0039-128X
- See references of WO 0162288A1
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
WO 0162288 A1 20010830; AU 2001241710 B2 20050721; AU 4171001 A 20010903; CA 2400874 A1 20010830; EP 1261371 A1 20021204; EP 1261371 A4 20050413; JP 2003523404 A 20030805
DOCDB simple family (application)
US 0105897 W 20010223; AU 2001241710 A 20010223; AU 4171001 A 20010223; CA 2400874 A 20010223; EP 01912991 A 20010223; JP 2001561352 A 20010223